BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Perucca P, Carter J, Vahle V, Gilliam FG. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology 2009;72:1223-9. [PMID: 19349601 DOI: 10.1212/01.wnl.0000345667.45642.61] [Cited by in Crossref: 149] [Cited by in F6Publishing: 123] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Jacoby A, Snape D, Baker GA. Determinants of Quality of Life in People with Epilepsy. Neurologic Clinics 2009;27:843-63. [DOI: 10.1016/j.ncl.2009.06.003] [Cited by in Crossref: 84] [Cited by in F6Publishing: 76] [Article Influence: 6.5] [Reference Citation Analysis]
2 Serratosa JM, Villanueva V, Kerling F, Kasper BS. Safety and tolerability of perampanel: a review of clinical trial data. Acta Neurol Scand 2013;127:30-5. [DOI: 10.1111/ane.12102] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
3 Martins H, Alonso N, Vidal-dourado M, Carbonel T, de Araújo Filho G, Caboclo L, Yacubian E, Guilhoto L. Are adverse effects of antiepileptic drugs different in symptomatic partial and idiopathic generalized epilepsies? The Portuguese–Brazilian validation of the Liverpool Adverse Events Profile. Epilepsy & Behavior 2011;22:511-7. [DOI: 10.1016/j.yebeh.2011.08.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
4 Nowinski CJ, Victorson D, Cavazos JE, Gershon R, Cella D. Neuro-QOL and the NIH Toolbox: implications for epilepsy. Therapy 2010;7:533-40. [DOI: 10.2217/thy.10.55] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
5 Zafar SF, Rosenthal ES, Postma EN, Sanches P, Ayub MA, Rajan S, Kim JA, Rubin DB, Lee H, Patel AB, Hsu J, Patorno E, Westover MB. Antiseizure Medication Treatment and Outcomes in Patients with Subarachnoid Hemorrhage Undergoing Continuous EEG Monitoring. Neurocrit Care 2021. [PMID: 34843082 DOI: 10.1007/s12028-021-01387-x] [Reference Citation Analysis]
6 Assis TRD, Nascimento OJM, Costa G, Bacellar A. Antiepileptic drugs patterns in elderly inpatients in a Brazilian tertiary center, Salvador, Brazil. Arq Neuro-Psiquiatr 2014;72:874-80. [DOI: 10.1590/0004-282x20140151] [Cited by in Crossref: 7] [Article Influence: 0.9] [Reference Citation Analysis]
7 Romoli M, Eusebi P, Siliquini S, Bedetti C, Calabresi P, Costa C. Liverpool Adverse Events Profile: Italian validation and predictive value for dropout from antiepileptic treatment in people with epilepsy. Epilepsy Behav 2018;81:111-4. [PMID: 29530336 DOI: 10.1016/j.yebeh.2018.01.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Guery D, Rheims S. Clinical Management of Drug Resistant Epilepsy: A Review on Current Strategies. Neuropsychiatr Dis Treat 2021;17:2229-42. [PMID: 34285484 DOI: 10.2147/NDT.S256699] [Reference Citation Analysis]
9 Olusanya A, Ogunleye O, Godman B, Fadare J, Danesi M. Adverse effects of carbamazepine monotherapy among patients in Nigeria: a pilot study and implications. Journal of Comparative Effectiveness Research 2017;6:33-42. [DOI: 10.2217/cer-2016-0057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
10 Fricke-Galindo I, Jung-Cook H, LLerena A, López-López M. Pharmacogenetics of adverse reactions to antiepileptic drugs. Neurologia (Engl Ed) 2018;33:165-76. [PMID: 25976948 DOI: 10.1016/j.nrl.2015.03.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
11 Elizebath R, Zhang E, Coe P, Gutierrez EG, Yang J, Krauss GL. Cenobamate treatment of focal-onset seizures: Quality of life and outcome during up to eight years of treatment. Epilepsy Behav 2021;116:107796. [PMID: 33567400 DOI: 10.1016/j.yebeh.2021.107796] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Suda T, Tatsuzawa Y, Mogi T, Yoshino A. Interictal dysphoric disorder in patients with localization-related epilepsy: Diagnostic relationships with DSM-IV psychiatric disorders and the impact of psychosocial burden. Epilepsy Behav 2016;54:142-7. [PMID: 26708065 DOI: 10.1016/j.yebeh.2015.11.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
13 Meador KJ, Loring DW, Boyd A, Echauz J, Laroche S, Velez-ruiz N, Korb P, Byrnes W, Dilley D, Borghs S, De Backer M, Story T, Dedeken P, Webster E. Randomized double-blind comparison of cognitive and EEG effects of lacosamide and carbamazepine. Epilepsy & Behavior 2016;62:267-75. [DOI: 10.1016/j.yebeh.2016.07.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
14 Sisterson ND, Kokkinos V. Neuromodulation of Epilepsy Networks. Neurosurg Clin N Am 2020;31:459-70. [PMID: 32475493 DOI: 10.1016/j.nec.2020.03.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
15 Mkrtchyan VR, Kaimovsky IL. [Pharmacoeconomic aspects of monotherapy of focal epilepsy]. Zh Nevrol Psikhiatr Im S S Korsakova 2019;119:92-8. [PMID: 32207738 DOI: 10.17116/jnevro201911911292] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Kwon OY, Park SP. What is the role of depressive symptoms among other predictors of quality of life in people with well-controlled epilepsy on monotherapy? Epilepsy Behav. 2011;20:528-532. [PMID: 21354863 DOI: 10.1016/j.yebeh.2011.01.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
17 Caplan R. Baseline psychiatric evaluations are needed to treat seizures. Epilepsy Curr 2012;12:236-7. [PMID: 23447722 DOI: 10.5698/1535-7511-12.6.236] [Reference Citation Analysis]
18 Sarangi SC, Kaur N, Tripathi M. Assessment of psychiatric and behavioral adverse effects of antiepileptic drugs monotherapy: Could they have a neuroendocrine correlation in persons with epilepsy? Epilepsy & Behavior 2019;100:106439. [DOI: 10.1016/j.yebeh.2019.07.040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
19 Kowski AB, Weissinger F, Gaus V, Fidzinski P, Losch F, Holtkamp M. Specific adverse effects of antiepileptic drugs — A true-to-life monotherapy study. Epilepsy & Behavior 2016;54:150-7. [DOI: 10.1016/j.yebeh.2015.11.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
20 Ross J, Stefan H, Schäuble B, Day R, Sander JW. European survey of the level of satisfaction of patients and physicians in the management of epilepsy in general practice. Epilepsy & Behavior 2010;19:36-42. [DOI: 10.1016/j.yebeh.2010.06.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
21 Chan B, Cheong EYK, Ng SFG, Chan YC, Lee QU, Chan KY. Evaluation of sleep disturbances in children with epilepsy: A questionnaire-based case–control study. Epilepsy & Behavior 2011;21:437-40. [DOI: 10.1016/j.yebeh.2011.05.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
22 Zaccara G, Giovannelli F, Cincotta M, Carelli A, Verrotti A. Clinical utility of eslicarbazepine: current evidence. Drug Des Devel Ther 2015;9:781-9. [PMID: 25709402 DOI: 10.2147/DDDT.S57409] [Cited by in Crossref: 25] [Cited by in F6Publishing: 7] [Article Influence: 3.6] [Reference Citation Analysis]
23 Cook AM, Bensalem-owen MK. Mechanisms of action of antiepileptic drugs. Therapy 2011;8:307-13. [DOI: 10.2217/thy.11.19] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
24 Sattar S, Kuperman R. Telehealth in pediatric epilepsy care: A rapid transition during the COVID-19 pandemic. Epilepsy Behav 2020;111:107282. [PMID: 32759065 DOI: 10.1016/j.yebeh.2020.107282] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
25 Kim S, Park S, Kwon O. Impact of depression and anxiety on adverse event profiles in Korean people with epilepsy. Epilepsy & Behavior 2015;46:185-91. [DOI: 10.1016/j.yebeh.2015.03.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
26 Jacoby A, Baker GA, Crossley J, Schachter S. Tools for assessing quality of life in epilepsy patients. Expert Rev Neurother 2013;13:1355-69. [PMID: 24215282 DOI: 10.1586/14737175.2013.850032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
27 Gao L, Xia L, Pan S, Xiong T, Li S. Reliability and validity of QOLIE-10 in measuring health-related quality of life (HRQoL) in Chinese epilepsy patients. Epilepsy Research 2014;108:565-75. [DOI: 10.1016/j.eplepsyres.2014.01.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
28 Dingen D, Van' T Veer M, Wammes-van der Heijden E, Lazeron RHC, van Mastrigt G, Majoie M. Evaluation of two anti-seizure medication strategies in refractory epilepsy patients from a tertiary center with complementary insights from data visualization. Epilepsy Res 2021;174:106667. [PMID: 33989886 DOI: 10.1016/j.eplepsyres.2021.106667] [Reference Citation Analysis]
29 Lamberink HJ, Otte WM, Geerts AT, Pavlovic M, Ramos-lizana J, Marson AG, Overweg J, Sauma L, Specchio LM, Tennison M, Cardoso TMO, Shinnar S, Schmidt D, Geleijns K, Braun KPJ. Individualised prediction model of seizure recurrence and long-term outcomes after withdrawal of antiepileptic drugs in seizure-free patients: a systematic review and individual participant data meta-analysis. The Lancet Neurology 2017;16:523-31. [DOI: 10.1016/s1474-4422(17)30114-x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 27] [Article Influence: 16.4] [Reference Citation Analysis]
30 May TW. Assessment of adverse effects of antiepileptic drugs: The patient's view. Epileptology 2013;1:46-54. [DOI: 10.1016/j.epilep.2013.01.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
31 Punia V, Honomichl R, Chandan P, Ellison L, Thompson N, Sivaraju A, Katzan I, George P, Newey C, Hantus S. Long-term continuation of anti-seizure medications after acute stroke. Ann Clin Transl Neurol 2021;8:1857-66. [PMID: 34355539 DOI: 10.1002/acn3.51440] [Reference Citation Analysis]
32 Kuzmanova R, Stefanova I, Velcheva I, Stambolieva K. Translation, cross-cultural adaptation, and validation of the Bulgarian version of the Liverpool Adverse Event Profile. Epilepsy Behav 2014;39:88-91. [PMID: 25238552 DOI: 10.1016/j.yebeh.2014.08.124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
33 Loizon M, Rheims S. Prise en charge d’une épilepsie pharmacorésistante. La Presse Médicale 2018;47:234-42. [DOI: 10.1016/j.lpm.2017.11.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
34 Shegog R, Begley CE. Clinic-Based Mobile Health Decision Support to Enhance Adult Epilepsy Self-Management: An Intervention Mapping Approach. Front Public Health 2017;5:256. [PMID: 29043247 DOI: 10.3389/fpubh.2017.00256] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
35 Orozco-hernández J, Quintero-moreno J, Marín-medina D, Castaño-montoya J, Hernández-coral P, Pineda M, Vélez J, Villada H, Martínez J, Lizcano A. Perfil clínico y sociodemográfico de la epilepsia en adultos de un centro de referencia de Colombia. Neurología 2019;34:437-44. [DOI: 10.1016/j.nrl.2017.02.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Beydemir Ş, Demir Y. Antiepileptic drugs: Impacts on human serum paraoxonase-1: BEYDEMIR AND DEMIR. J Biochem Mol Toxicol 2017;31:e21889. [DOI: 10.1002/jbt.21889] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 6.5] [Reference Citation Analysis]
37 Budikayanti A, Qadri LM, Syeban Z, Indrawati LA, Octaviana F. Adverse Events of Antiepileptic Drugs Using Indonesian Version of Liverpool Adverse Events Profile. Neurol Res Int 2018;2018:8490639. [PMID: 30595918 DOI: 10.1155/2018/8490639] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
38 Amerineni R, Sun H, Lee H, Hsu J, Patorno E, Westover MB, Zafar SF. Using electronic health data to explore effectiveness of ICU EEG and anti-seizure treatment. Ann Clin Transl Neurol 2021;8:2270-9. [PMID: 34802196 DOI: 10.1002/acn3.51478] [Reference Citation Analysis]
39 Bergey GK, Morrell MJ, Mizrahi EM, Goldman A, King-Stephens D, Nair D, Srinivasan S, Jobst B, Gross RE, Shields DC, Barkley G, Salanova V, Olejniczak P, Cole A, Cash SS, Noe K, Wharen R, Worrell G, Murro AM, Edwards J, Duchowny M, Spencer D, Smith M, Geller E, Gwinn R, Skidmore C, Eisenschenk S, Berg M, Heck C, Van Ness P, Fountain N, Rutecki P, Massey A, O'Donovan C, Labar D, Duckrow RB, Hirsch LJ, Courtney T, Sun FT, Seale CG. Long-term treatment with responsive brain stimulation in adults with refractory partial seizures. Neurology 2015;84:810-7. [PMID: 25616485 DOI: 10.1212/WNL.0000000000001280] [Cited by in Crossref: 321] [Cited by in F6Publishing: 119] [Article Influence: 45.9] [Reference Citation Analysis]
40 Henning O, Medalen TEM, Nakken KO, Lossius MI. How often do doctors discuss drug withdrawal with their seizure-free patients with epilepsy? Epilepsy Behav 2020;108:107095. [PMID: 32320921 DOI: 10.1016/j.yebeh.2020.107095] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Zafar SF, Postma EN, Biswal S, Boyle EJ, Bechek S, O'Connor K, Shenoy A, Kim J, Shafi MS, Patel AB, Rosenthal ES, Westover MB. Effect of epileptiform abnormality burden on neurologic outcome and antiepileptic drug management after subarachnoid hemorrhage. Clin Neurophysiol 2018;129:2219-27. [PMID: 30212805 DOI: 10.1016/j.clinph.2018.08.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
42 Park YS, Cosgrove GR, Madsen JR, Eskandar EN, Hochberg LR, Cash SS, Truccolo W. Early Detection of Human Epileptic Seizures Based on Intracortical Microelectrode Array Signals. IEEE Trans Biomed Eng 2020;67:817-31. [PMID: 31180831 DOI: 10.1109/TBME.2019.2921448] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
43 Bastani A, Young E, Shaqiri B, Walch R, Manthena P, Weimer S, Kayyali H. Screening electroencephalograms are feasible in the emergency department. J Telemed Telecare 2014;20:259-62. [DOI: 10.1177/1357633x14537775] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
44 Wieshmann UC, Tan GM, Baker G. Self-reported symptoms in patients on antiepileptic drugs in monotherapy. Acta Neurol Scand 2011;124:355-8. [PMID: 21973277 DOI: 10.1111/j.1600-0404.2011.01488.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
45 Josephson CB, Engbers JDT, Jette N, Patten SB, Sajobi TT, Marshall D, Lowerison M, Wiebe S. Prescription trends and psychiatric symptoms following first receipt of one of seven common antiepileptic drugs in general practice. Epilepsy Behav 2018;84:49-55. [PMID: 29753294 DOI: 10.1016/j.yebeh.2018.04.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Bruna J, Miró J, Velasco R. Epilepsy in glioblastoma patients: basic mechanisms and current problems in treatment. Expert Rev Clin Pharmacol 2013;6:333-44. [PMID: 23656344 DOI: 10.1586/ecp.13.12] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
47 de Kinderen RJ, Evers SM, Rinkens R, Postulart D, Vader CI, Majoie MH, Aldenkamp AP. Side-effects of antiepileptic drugs: The economic burden. Seizure 2014;23:184-90. [DOI: 10.1016/j.seizure.2013.11.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
48 Krajewski S, Wójcik M, Harat M, Furtak J. Influence of Epilepsy on the Quality of Life of Patients with Brain Tumors. Int J Environ Res Public Health 2021;18:6390. [PMID: 34204841 DOI: 10.3390/ijerph18126390] [Reference Citation Analysis]
49 Hosohata K, Inada A, Oyama S, Niinomi I, Wakabayashi T, Iwanaga K. Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database. Clin Drug Investig 2019;39:363-8. [PMID: 30689189 DOI: 10.1007/s40261-019-00754-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
50 Taylor RS, Sander JW, Taylor RJ, Baker GA. Predictors of health-related quality of life and costs in adults with epilepsy: a systematic review. Epilepsia 2011;52:2168-80. [PMID: 21883177 DOI: 10.1111/j.1528-1167.2011.03213.x] [Cited by in Crossref: 196] [Cited by in F6Publishing: 174] [Article Influence: 17.8] [Reference Citation Analysis]
51 Rektor I, Krauss GL, Bar M, Biton V, Klapper JA, Vaiciene-magistris N, Kuba R, Squillacote D, Gee M, Kumar D. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand 2012. [DOI: 10.1111/ane.12001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 0.6] [Reference Citation Analysis]
52 Duy PQ, He M, He Z, Kahle KT. Preclinical insights into therapeutic targeting of KCC2 for disorders of neuronal hyperexcitability. Expert Opin Ther Targets 2020;24:629-37. [PMID: 32336175 DOI: 10.1080/14728222.2020.1762174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Tombini M, Assenza G, Quintiliani L, Ricci L, Lanzone J, Di Lazzaro V. Epilepsy and quality of life: what does really matter? Neurol Sci 2021;42:3757-65. [PMID: 33449244 DOI: 10.1007/s10072-020-04990-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Begley C, Shegog R, Harding A, Goldsmith C, Hope O, Newmark M. Longitudinal feasibility of MINDSET: a clinic decision aid for epilepsy self-management. Epilepsy Behav 2015;44:143-50. [PMID: 25705825 DOI: 10.1016/j.yebeh.2014.12.031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
55 Miano S, Bruni O, Aricò D, Elia M, Ferri R. Polysomnographic assessment of sleep disturbances in children with developmental disabilities and seizures. Neurol Sci 2010;31:575-83. [PMID: 20506030 DOI: 10.1007/s10072-010-0291-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
56 Meador KJ, Brashear HR, Wiegand F, Zannikos P, Novak G. Cognitive effects of carisbamate in randomized, placebo-controlled, healthy-volunteer, multidose studies. Epilepsy Behav 2011;22:324-30. [PMID: 21849260 DOI: 10.1016/j.yebeh.2011.07.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
57 Yılmaz Ü, Yılmaz TS, Dizdarer G, Akıncı G, Güzel O, Tekgül H. Efficacy and tolerability of the first antiepileptic drug in children with newly diagnosed idiopathic epilepsy. Seizure 2014;23:252-9. [DOI: 10.1016/j.seizure.2013.12.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
58 Melikyan E, Guekht A, Milchakova L, Lebedeva A, Bondareva I, Gusev E. Health-related quality of life in Russian adults with epilepsy: The effect of socio-demographic and clinical factors. Epilepsy & Behavior 2012;25:670-5. [DOI: 10.1016/j.yebeh.2012.09.042] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
59 Gauffin H, Landtblom AM, Räty L. Self-esteem and sense of coherence in young people with uncomplicated epilepsy: a 5-year follow-up. Epilepsy Behav 2010;17:520-4. [PMID: 20227922 DOI: 10.1016/j.yebeh.2010.01.167] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
60 de Toledo M, Valladares-Salado L, Cebrian-Escudero J, Diaz-Perez C, de la Fuente E, Ferreiros R, Sanz-Sanz E, Vega-Piris L, Lagares A, Ovejero-Benito MC, Sobrado M. Pharmacokinetic variability of eslicarbazepine in real clinical practice. Epilepsy Behav 2021;124:108284. [PMID: 34521058 DOI: 10.1016/j.yebeh.2021.108284] [Reference Citation Analysis]
61 Zaccara G, Giovannelli F, Schmidt D. Placebo and nocebo responses in drug trials of epilepsy. Epilepsy & Behavior 2015;43:128-34. [DOI: 10.1016/j.yebeh.2014.12.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
62 Ayalew MB, Muche EA. Patient reported adverse events among epileptic patients taking antiepileptic drugs. SAGE Open Med 2018;6:2050312118772471. [PMID: 29760918 DOI: 10.1177/2050312118772471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
63 Sharma S, Kwan P. The safety of treating newly diagnosed epilepsy. Expert Opin Drug Saf 2019;18:273-83. [PMID: 30943798 DOI: 10.1080/14740338.2019.1602607] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
64 Romoli M, Costa C, Siliquini S, Corbelli I, Eusebi P, Bedetti C, Caproni S, Cupini LM, Calabresi P, Sarchielli P. Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events? Cephalalgia 2018;38:274-82. [PMID: 27956547 DOI: 10.1177/0333102416683925] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
65 Janmohamed M, Lawn N, Spilsbury K, Chan J, Dunne J. Starting a new anti-seizure medication in drug-resistant epilepsy: Add-on or substitute? Epilepsia 2021;62:228-37. [PMID: 33236785 DOI: 10.1111/epi.16765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Zaccara G, Tramacere L. Antiepileptic drugs. A worldwide yearly survey of new data in adverse drug reactions. Elsevier; 2011. pp. 125-204. [DOI: 10.1016/b978-0-444-53741-6.00007-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
67 Tatum WO. Antiepileptic drugs: adverse effects and drug interactions. Continuum (Minneap Minn) 2010;16:136-58. [PMID: 22810319 DOI: 10.1212/01.CON.0000368236.41986.24] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
68 Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain NB. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav 2015;52:119-27. [PMID: 26414341 DOI: 10.1016/j.yebeh.2015.09.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
69 Baftiu A, Lima MH, Svendsen K, Larsson PG, Johannessen SI, Landmark CJ. Safety aspects of antiepileptic drugs—a population-based study of adverse effects relative to changes in utilisation. Eur J Clin Pharmacol 2019;75:1153-60. [DOI: 10.1007/s00228-019-02678-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
70 Cramer JA. Tolerability of antiepileptic drugs: can we determine differences? Epilepsy Behav 2012;23:187-92. [PMID: 22366050 DOI: 10.1016/j.yebeh.2011.11.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
71 Zaccara G, Perucca P, Loiacono G, Giovannelli F, Verrotti A. The adverse event profile of lacosamide: A systematic review and meta-analysis of randomized controlled trials: The Adverse Event Profile of Lacosamide. Epilepsia 2013;54:66-74. [DOI: 10.1111/j.1528-1167.2012.03589.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 6.2] [Reference Citation Analysis]
72 Seo J, Lee G, Park S. Apathy in people with epilepsy and its clinical significance: A case-control study. Seizure 2017;51:80-6. [DOI: 10.1016/j.seizure.2017.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
73 Chu SS, Tan G, Wang XP, Liu L. Validation of the predictive model for seizure recurrence after withdrawal of antiepileptic drugs. Epilepsy Behav 2021;114:106987. [PMID: 32444329 DOI: 10.1016/j.yebeh.2020.106987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
74 Mevaag M, Henning O, Baftiu A, Granas AG, Johannessen SI, Nakken KO, Johannessen Landmark C. Discrepancies between physicians' prescriptions and patients' use of antiepileptic drugs. Acta Neurol Scand 2017;135:80-7. [DOI: 10.1111/ane.12578] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
75 Sun FT, Morrell MJ. The RNS System: responsive cortical stimulation for the treatment of refractory partial epilepsy. Expert Review of Medical Devices 2014;11:563-72. [DOI: 10.1586/17434440.2014.947274] [Cited by in Crossref: 109] [Cited by in F6Publishing: 89] [Article Influence: 13.6] [Reference Citation Analysis]
76 Nixon A, Kerr C, Breheny K, Wild D. Patient Reported Outcome (PRO) assessment in epilepsy: a review of epilepsy-specific PROs according to the Food and Drug Administration (FDA) regulatory requirements. Health Qual Life Outcomes 2013;11:38. [PMID: 23497117 DOI: 10.1186/1477-7525-11-38] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
77 Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011;52:826-36. [PMID: 21320112 DOI: 10.1111/j.1528-1167.2010.02966.x] [Cited by in Crossref: 120] [Cited by in F6Publishing: 105] [Article Influence: 10.9] [Reference Citation Analysis]
78 Liang X, Yu N, Zhang YF, Gu L, Di Q. Prognostic implications of persistent interictal epileptiform discharges on antiseizure medication withdrawal in patients with epilepsy in five-year remission. Seizure 2022;94:100-6. [PMID: 34883461 DOI: 10.1016/j.seizure.2021.11.009] [Reference Citation Analysis]
79 Cano-López I, Hampel KG, Garcés M, Villanueva V, González-Bono E. Quality of life in drug-resistant epilepsy: relationships with negative affectivity, memory, somatic symptoms and social support. J Psychosom Res 2018;114:31-7. [PMID: 30314576 DOI: 10.1016/j.jpsychores.2018.09.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
80 Steinhoff BJ, Klein P, Klitgaard H, Laloyaux C, Moseley BD, Ricchetti-Masterson K, Rosenow F, Sirven JI, Smith B, Stern JM, Toledo M, Zipfel PA, Villanueva V. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review. Epilepsy Behav 2021;118:107939. [PMID: 33839453 DOI: 10.1016/j.yebeh.2021.107939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 Izadi A, Ondek K, Schedlbauer A, Keselman I, Shahlaie K, Gurkoff G. Clinically indicated electrical stimulation strategies to treat patients with medically refractory epilepsy. Epilepsia Open 2018;3:198-209. [PMID: 30564779 DOI: 10.1002/epi4.12276] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
82 Verrotti A, Prezioso G, Di Sabatino F, Franco V, Chiarelli F, Zaccara G. The adverse event profile of levetiracetam: A meta-analysis on children and adults. Seizure 2015;31:49-55. [DOI: 10.1016/j.seizure.2015.07.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 7.1] [Reference Citation Analysis]
83 Sivapalarajah S, Krishnakumar M, Bickerstaffe H, Chan Y, Clarkson J, Hampden-Martin A, Mirza A, Tanti M, Marson A, Pirmohamed M, Mirza N. The prescribable drugs with efficacy in experimental epilepsies (PDE3) database for drug repurposing research in epilepsy. Epilepsia 2018;59:492-501. [PMID: 29341109 DOI: 10.1111/epi.13994] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
84 Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, Squillacote D, Kumar D. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 2012;125:8-15. [PMID: 21883097 DOI: 10.1111/j.1600-0404.2011.01588.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 6.7] [Reference Citation Analysis]
85 Matsunuma S, Sunaga S, Hoshiai A, Arai T, Jimbo H, Yoshimoto K. Psychiatric disorders of the combination of levetiracetam either with lacosamide or perampanel: a retrospective cohort study. Int J Clin Pharm 2021. [PMID: 34121153 DOI: 10.1007/s11096-021-01274-7] [Reference Citation Analysis]
86 Alexander HB, Broshek DK, Quigg M. Quality of life in adults with epilepsy is associated with anticonvulsant polypharmacy independent of seizure status. Epilepsy & Behavior 2018;78:96-9. [DOI: 10.1016/j.yebeh.2017.11.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
87 Stern JM, Labiner DM, Gilliam FG, Penovich PE, Onofrey M, Eagan CA, Holmes GL. More effective assessment of adverse effects and comorbidities in epilepsy: Results of a Phase II communication study. Epilepsy & Behavior 2011;22:552-6. [DOI: 10.1016/j.yebeh.2011.06.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
88 de la Loge C, Dimova S, Mueller K, Phillips G, Durgin TL, Wicks P, Borghs S. PatientsLikeMe® Online Epilepsy Community: Patient characteristics and predictors of poor health-related quality of life. Epilepsy & Behavior 2016;63:20-8. [DOI: 10.1016/j.yebeh.2016.07.035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
89 Gajate-García V, Gutiérrez-Viedma Á, Romeral-Jiménez M, Serrano-García I, Parejo-Carbonell B, Montalvo-Moraleda T, Valls-Carbó A, García-Morales I. Seizures in the Emergency Department: clinical and diagnostic data from a series of 153 patients. Neurologia (Engl Ed) 2021:S2173-5808(21)00181-4. [PMID: 34836845 DOI: 10.1016/j.nrleng.2020.02.011] [Reference Citation Analysis]
90 Perucca P, Jacoby A, Marson AG, Baker GA, Lane S, Benn EK, Thurman DJ, Hauser WA, Gilliam FG, Hesdorffer DC. Adverse antiepileptic drug effects in new-onset seizures: a case-control study. Neurology 2011;76:273-9. [PMID: 21242496 DOI: 10.1212/WNL.0b013e318207b073] [Cited by in Crossref: 59] [Cited by in F6Publishing: 13] [Article Influence: 5.4] [Reference Citation Analysis]
91 Akdemir V, Sut N, Guldiken B. Factors affecting the quality of life in drug-resistant epilepsy patients. Acta Neurol Belg 2016;116:513-8. [PMID: 26943462 DOI: 10.1007/s13760-016-0622-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
92 Tabaeizadeh M, Aboul Nour H, Shoukat M, Sun H, Jin J, Javed F, Kassa S, Edhi M, Bordbar E, Gallagher J, Moura VJ, Ghanta M, Shao YP, Cole AJ, Rosenthal ES, Westover MB, Zafar SF. Burden of Epileptiform Activity Predicts Discharge Neurologic Outcomes in Severe Acute Ischemic Stroke. Neurocrit Care 2020;32:697-706. [PMID: 32246435 DOI: 10.1007/s12028-020-00944-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
93 Milovanović M, Martinović Ž, Tošković O. Determinants of quality of life in people with epilepsy in Serbia. Epilepsy & Behavior 2014;31:160-6. [DOI: 10.1016/j.yebeh.2013.12.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
94 Khan TM, Alhafez AA, Syed Sulaiman SA, Bin Chia DW. Safety of pregabalin among hemodialysis patients suffering from uremic pruritus. Saudi Pharm J 2015;23:614-20. [PMID: 26702255 DOI: 10.1016/j.jsps.2014.10.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
95 Sarro GD, Paola ED, Gratteri S, Gareri P, Rispoli V, Siniscalchi A, Tripepi G, Gallelli L, Citraro R, Russo E. Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice. Pharmacol Res. 2012;65:285-296. [PMID: 22107891 DOI: 10.1016/j.phrs.2011.11.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
96 Josephson CB, Wiebe S. Precision Medicine: Academic dreaming or clinical reality? Epilepsia 2021;62 Suppl 2:S78-89. [PMID: 33205406 DOI: 10.1111/epi.16739] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
97 Taylor J, Jacoby A, Baker GA, Marson AG, Ring A, Whitehead M. Factors predictive of resilience and vulnerability in new-onset epilepsy: Resilience in New-Onset Epilepsy. Epilepsia 2011;52:610-8. [DOI: 10.1111/j.1528-1167.2010.02775.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
98 Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Buchsbaum R, Detyniecki K. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy & Behavior 2017;76:24-31. [DOI: 10.1016/j.yebeh.2017.08.039] [Cited by in Crossref: 107] [Cited by in F6Publishing: 90] [Article Influence: 21.4] [Reference Citation Analysis]
99 Nomura T, Hawkins NA, Kearney JA, George AL Jr, Contractor A. Potentiating α2 subunit containing perisomatic GABAA receptors protects against seizures in a mouse model of Dravet syndrome. J Physiol 2019;597:4293-307. [PMID: 31045243 DOI: 10.1113/JP277651] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
100 Heck CN, King-Stephens D, Massey AD, Nair DR, Jobst BC, Barkley GL, Salanova V, Cole AJ, Smith MC, Gwinn RP, Skidmore C, Van Ness PC, Bergey GK, Park YD, Miller I, Geller E, Rutecki PA, Zimmerman R, Spencer DC, Goldman A, Edwards JC, Leiphart JW, Wharen RE, Fessler J, Fountain NB, Worrell GA, Gross RE, Eisenschenk S, Duckrow RB, Hirsch LJ, Bazil C, O'Donovan CA, Sun FT, Courtney TA, Seale CG, Morrell MJ. Two-year seizure reduction in adults with medically intractable partial onset epilepsy treated with responsive neurostimulation: final results of the RNS System Pivotal trial. Epilepsia 2014;55:432-41. [PMID: 24621228 DOI: 10.1111/epi.12534] [Cited by in Crossref: 325] [Cited by in F6Publishing: 251] [Article Influence: 40.6] [Reference Citation Analysis]
101 Guery D, Rheims S. Is the mechanism of action of antiseizure drugs a key element in the choice of treatment? Fundam Clin Pharmacol 2021;35:552-63. [PMID: 33090514 DOI: 10.1111/fcp.12614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
102 Jasionis A, Jasionytė G, Mameniškienė R. Tolerability of antiseizure medicines using Lithuanian version of the Liverpool Adverse Events Profile. Epilepsy Behav 2021;124:108371. [PMID: 34757263 DOI: 10.1016/j.yebeh.2021.108371] [Reference Citation Analysis]
103 Lin J, Ding S, Li X, Hua Y, Wang X, He R, Du Y, Xia N, Chen Y, Zhu Z, Zheng R, Xu H. External validation and comparison of two prediction models for seizure recurrence after the withdrawal of antiepileptic drugs in adult patients. Epilepsia 2020;61:115-24. [DOI: 10.1111/epi.16402] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
104 Balzekas I, Sladky V, Nejedly P, Brinkmann BH, Crepeau D, Mivalt F, Gregg NM, Pal Attia T, Marks VS, Wheeler L, Riccelli TE, Staab JP, Lundstrom BN, Miller KJ, Van Gompel J, Kremen V, Croarkin PE, Worrell GA. Invasive Electrophysiology for Circuit Discovery and Study of Comorbid Psychiatric Disorders in Patients With Epilepsy: Challenges, Opportunities, and Novel Technologies. Front Hum Neurosci 2021;15:702605. [PMID: 34381344 DOI: 10.3389/fnhum.2021.702605] [Reference Citation Analysis]
105 Yogarajah M, Mula M. The Role of Antiepileptic Drugs. In: Mula M, editor. Neuropsychiatric Symptoms of Epilepsy. Cham: Springer International Publishing; 2016. pp. 333-60. [DOI: 10.1007/978-3-319-22159-5_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
106 Tan G, Li X, Niu R, Chen D, Wang H, Zhu L, Gong Q, Liu L. Microstructural features of the cerebral cortex: Implications for predicting epilepsy relapse after drug withdrawal. Brain Res 2021;1751:147200. [PMID: 33166509 DOI: 10.1016/j.brainres.2020.147200] [Reference Citation Analysis]
107 Yamamoto Y, Shiratani Y, Asai S, Usui N, Nishida T, Imai K, Kagawa Y, Takahashi Y. Risk factors for psychiatric adverse effects associated with perampanel therapy. Epilepsy Behav 2021;124:108356. [PMID: 34662853 DOI: 10.1016/j.yebeh.2021.108356] [Reference Citation Analysis]
108 Fricke-Galindo I, LLerena A, Jung-Cook H, López-López M. Carbamazepine adverse drug reactions. Expert Rev Clin Pharmacol 2018;11:705-18. [PMID: 29898616 DOI: 10.1080/17512433.2018.1486707] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
109 Kubova H. Side Effects of Antiepileptic Drugs. In: Talevi A, Rocha L, editors. Antiepileptic Drug Discovery. New York: Springer; 2016. pp. 329-50. [DOI: 10.1007/978-1-4939-6355-3_17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
110 Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11:792-802. [PMID: 22832500 DOI: 10.1016/s1474-4422(12)70153-9] [Cited by in Crossref: 300] [Cited by in F6Publishing: 92] [Article Influence: 30.0] [Reference Citation Analysis]
111 Saetre E, Abdelnoor M, Perucca E, Taubøll E, Isojärvi J, Gjerstad L. Antiepileptic drugs and quality of life in the elderly: Results from a randomized double-blind trial of carbamazepine and lamotrigine in patients with onset of epilepsy in old age. Epilepsy & Behavior 2010;17:395-401. [DOI: 10.1016/j.yebeh.2009.12.026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
112 Sulak D, Saneto R, Goldstein B. The current status of artisanal cannabis for the treatment of epilepsy in the United States. Epilepsy Behav 2017;70:328-33. [PMID: 28254350 DOI: 10.1016/j.yebeh.2016.12.032] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 7.8] [Reference Citation Analysis]
113 Grinspan ZM, Patel AD, Shellhaas RA, Berg AT, Axeen ET, Bolton J, Clarke DF, Coryell J, Gaillard WD, Goodkin HP, Koh S, Kukla A, Mbwana JS, Morgan LA, Singhal NS, Storey MM, Yozawitz EG, Abend NS, Fitzgerald MP, Fridinger SE, Helbig I, Massey SL, Prelack MS, Buchhalter J; Pediatric Epilepsy Learning Healthcare System. Design and implementation of electronic health record common data elements for pediatric epilepsy: Foundations for a learning health care system. Epilepsia 2021;62:198-216. [PMID: 33368200 DOI: 10.1111/epi.16733] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
114 Luoni C, Bisulli F, Canevini MP, De Sarro G, Fattore C, Galimberti CA, Gatti G, La Neve A, Muscas G, Specchio LM. Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia. 2011;52:2181-2191. [PMID: 22136077 DOI: 10.1111/j.1528-1167.2011.03325.x] [Cited by in Crossref: 173] [Cited by in F6Publishing: 147] [Article Influence: 17.3] [Reference Citation Analysis]
115 Gilliam FG, Black KJ, Carter J, Freedland KE, Sheline YI, Tsai WY, Lustman PJ. A Trial of Sertraline or Cognitive Behavior Therapy for Depression in Epilepsy. Ann Neurol 2019;86:552-60. [PMID: 31359460 DOI: 10.1002/ana.25561] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
116 Jacoby A, Snape D, Lane S, Baker GA. Self-reported anxiety and sleep problems in people with epilepsy and their association with quality of life. Epilepsy Behav 2015;43:149-58. [PMID: 25599986 DOI: 10.1016/j.yebeh.2014.09.071] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
117 Chang HH, Sung PS, Liao WC, Chang AYW, Hsiao YH, Fu TF, Huang CY, Huang CW. An Open Pilot Study of the Effect and Tolerability of Add-On Multivitamin Therapy in Patients with Intractable Focal Epilepsy. Nutrients 2020;12:E2359. [PMID: 32784611 DOI: 10.3390/nu12082359] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
118 Wiglusz MS, Landowski J, Cubała WJ. Interictal dysphoric disorder of epilepsy: A continuing diagnostic challenge. Epilepsy Behav 2019;95:34-8. [PMID: 31022662 DOI: 10.1016/j.yebeh.2019.03.036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
119 Machado-Alba JE, Calvo-Torres LF, García-Betancur S, Aguirre-Novoa A, Bañol-Giraldo AM. Drug utilisation study in patients receiving antiepileptic drugs in Colombia. Neurologia 2016;31:89-96. [PMID: 26304659 DOI: 10.1016/j.nrl.2015.06.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
120 Park KM, Shin KJ, Ha SY, Park J, Kim SE, Kim HC, Lee JW, Kim SE. Can the adverse effects of antiepileptic drugs be detected in saccadic eye movements? Seizure 2015;25:33-6. [PMID: 25645633 DOI: 10.1016/j.seizure.2014.12.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
121 Gajate-garcía V, Gutiérrez-viedma Á, Romeral-jiménez M, Serrano-garcía I, Parejo-carbonell B, Montalvo-moraleda T, Valls-carbó A, García-morales I. Crisis epilépticas en urgencias: aspectos clínicos y diagnósticos de una serie de 153 pacientes. Neurología 2020. [DOI: 10.1016/j.nrl.2020.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
122 Perucca P, Mula M. Antiepileptic drug effects on mood and behavior: Molecular targets. Epilepsy & Behavior 2013;26:440-9. [DOI: 10.1016/j.yebeh.2012.09.018] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 7.1] [Reference Citation Analysis]
123 Alsfouk BAA, Brodie MJ, Walters M, Kwan P, Chen Z. Tolerability of Antiseizure Medications in Individuals With Newly Diagnosed Epilepsy. JAMA Neurol 2020;77:574-81. [PMID: 32091535 DOI: 10.1001/jamaneurol.2020.0032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
124 Lancman ME, Fertig EJ, Trobliger RW, Perrine K, Myers L, Iyengar SS, Malik M. The effects of lacosamide on cognition, quality-of-life measures, and quality of life in patients with refractory partial epilepsy. Epilepsy & Behavior 2016;61:27-33. [DOI: 10.1016/j.yebeh.2016.04.049] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
125 Pellock JM, Brittain ST. Use of computer simulations to test the concept of dose forgiveness in the era of extended-release (XR) drugs. Epilepsy Behav 2016;55:21-3. [PMID: 26724400 DOI: 10.1016/j.yebeh.2015.11.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
126 Usui N, Akamatsu N, Nakasato N, Ohnishi A, Kaneko S, Hiramatsu H, Saeki K, Miyagishi H, Inoue Y. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy. Seizure 2018;62:26-32. [DOI: 10.1016/j.seizure.2018.09.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
127 Shegog R, Begley CE, Harding A, Dubinsky S, Goldsmith C, Hope O, Newmark M. Description and feasibility of MINDSET: A clinic decision aid for epilepsy self-management. Epilepsy & Behavior 2013;29:527-36. [DOI: 10.1016/j.yebeh.2013.09.023] [Cited by in Crossref: 8] [Article Influence: 0.9] [Reference Citation Analysis]
128 Mirza N, Stevelink R, Taweel B, Koeleman BPC, Marson AG; International League Against Epilepsy Consortium on Complex Epilepsies . Using common genetic variants to find drugs for common epilepsies. Brain Commun 2021;3:fcab287. [PMID: 34988442 DOI: 10.1093/braincomms/fcab287] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Zakrzewska JM, Palmer J, Ettlin DA, Obermann M, Giblin GM, Morisset V, Tate S, Gunn K. Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia. Trials 2013;14:402. [PMID: 24267010 DOI: 10.1186/1745-6215-14-402] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
130 Lamberink HJ, Otte WM, Blümcke I, Braun KPJ; European Epilepsy Brain Bank writing group., study group., European Reference Network EpiCARE. Seizure outcome and use of antiepileptic drugs after epilepsy surgery according to histopathological diagnosis: a retrospective multicentre cohort study. Lancet Neurol 2020;19:748-57. [PMID: 32822635 DOI: 10.1016/S1474-4422(20)30220-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 16.5] [Reference Citation Analysis]
131 Choi SA, Lim K, Baek H, Yoo S, Cho A, Kim H, Hwang H, Kim KJ. Impact of mobile health application on data collection and self-management of epilepsy. Epilepsy Behav 2021;119:107982. [PMID: 33946011 DOI: 10.1016/j.yebeh.2021.107982] [Reference Citation Analysis]
132 Contento M, Bertaccini B, Biggi M, Magliani M, Failli Y, Rosati E, Massacesi L, Paganini M. Prediction of seizure recurrence risk following discontinuation of antiepileptic drugs. Epilepsia 2021;62:2159-70. [PMID: 34250596 DOI: 10.1111/epi.16993] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
133 Mula M, von Oertzen TJ, Cock HR, Yogarajah M, Lozsadi DA, Agrawal N. Fatigue during treatment with antiepileptic drugs: A levetiracetam-specific adverse event? Epilepsy & Behavior 2017;72:17-21. [DOI: 10.1016/j.yebeh.2017.04.030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]